Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7156842 | 1.00 | KMT2A (0.55) | KMT2AMEN1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6556806 | 0.93 | KMT2A (0.58) | KMT2AMEN1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6555037 | 0.91 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6555033 | 0.91 | ALDH1A1 (0.48) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6554770 | 0.91 | ALDH1A1 (0.58) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6554757 | 0.91 | ALDH1A1 (0.58) | KMT2AMEN1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6555032 | 0.89 | KMT2A (0.50) | KMT2AMEN1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6555027 | 0.89 | KMT2A (0.50) | KMT2AMEN1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6553342 | 0.86 | MEN1 (0.56) | KMT2AMEN1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6553333 | 0.86 | MEN1 (0.56) | KMT2AMEN1GAASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1135368-B1 | ALPHA-SULFIN- AND ALPHA-SULFON-AMINO ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-02-25 | — | — | EP | disclosed |
| US-6538016-B2 | For controlling and preventing an infestation of crop plants by phytopathogenic microorganisms, preferably fungi | SYNGENTA PARTICIPATIONS AG (CH) | 2003-03-25 | — | — | US | disclosed |
| US-20020082452-A1 | alpha-sulfin-and alpha-sulfonamino acid amides | SYNGENTA PARTICIPATIONS AG (CH) | 2002-06-27 | — | — | US | disclosed |
| EP-1135368-A2 | ALPHA-SULFIN- AND ALPHA-SULFON-AMINO ACID AMIDES | Syngenta Participations AG (CH) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032568-A2 | $G(A)-SULFIN- AND $G(A)-SULFONAMINO ACID AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2000-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082452-A1 | alpha-sulfin-and alpha-sulfonamino acid amides | SULT1A1, CBR1, SULT2A1 | KMT2A 2647/4885MEN1 3649/4885GAA 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.